| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aloe vera — a medicinal succulent (Aloe barbadensis Miller) used as a complex botanical mixture whose clinically used preparations typically derive from (i) the inner leaf gel (polysaccharide-rich) and/or (ii) whole-leaf extracts containing anthraquinones. It is best classified as a botanical/natural product mixture (not a single agent). Common abbreviations include AV (Aloe vera). Key bioactives often discussed in oncology-adjacent literature include polysaccharides such as acemannan (immunomodulatory/wound-healing biomaterial profile) and anthraquinones such as aloe-emodin/emodin/aloin (more directly cytotoxic in vitro, but also linked to GI toxicity/carcinogenic hazard signals in certain whole-leaf preparations). Primary mechanisms (ranked):
Bioavailability / PK relevance: Aloe preparations are heterogeneous. High–molecular-weight gel polysaccharides (e.g., acemannan) have limited systemic bioavailability and are most relevant for local mucosal/skin exposure or immune-adjacent effects; anthraquinones are more systemically absorbable but undergo metabolism and are constrained by GI tolerance and safety concerns. “Decolorized/low-anthraquinone” products differ materially from nondecolorized whole-leaf extracts. In-vitro vs systemic exposure relevance: Many reported anticancer effects use crude extracts or isolated anthraquinones at concentrations that may exceed typical achievable systemic levels from oral supplements; supportive-care benefits (skin/mucosa) are more plausibly local exposure–driven. Clinical evidence status: Predominantly preclinical for direct anticancer activity. Human evidence is mainly supportive-care (e.g., radiation dermatitis and oral mucositis), with mixed RCT outcomes and heterogeneous formulations; there is no high-quality evidence establishing Aloe vera as a primary anticancer therapy. Aloe vera Therapeutic properties include: anti-microbial, anti-viral, anti-cancer, anti-oxidant, anti-inflammatory, skin protection, wound healing, and regulation of blood glucose and cholesterol.active constituents, such as aloe-emodin and acemannan. • Aloe vera extracts harbor antioxidant compounds that can scavenge free radicals, protecting cells from oxidative damage—a factor in aging and cancer development. Aloe vera’s blend of bioactive compounds offers a range of biological activities—including anti-inflammatory, antioxidant, immunomodulatory, and wound-healing effects—that have attracted interest for complementary roles in health maintenance and cancer supportive care. While it is not a primary anticancer agent, its potential to mitigate treatment side effects, enhance immune responses, and possibly contribute to chemoprevention makes it a subject of ongoing research. Aloe vera — mechanistic axes relevant to cancer and supportive care
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 5362- | AV, | Anti-cancer effects of aloe-emodin: a systematic review |
| - | Review, | Var, | NA |
| 5365- | AV, | Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:28 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid